Position in NAMS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,333,333
+$261,767 QoQ
Shares Held
39,343
+17.5% QoQ
Ownership
0.033%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#105
of 197 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NAMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Legal & General Group Plc holds $3,286,710,193 across 292 Biotechnology names. NAMS ranks #96 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,870,015 | $928,892,550 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
759,971 | $473,872,316 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
924,561 | $278,320,596 | |
| 4 | RPRX |
Royalty Pharma plc
|
3,800,504 | $213,094,258 | |
| 5 | INCY |
Incyte Corp
|
1,605,980 | $182,053,892 | |
| 6 | ARGX |
Argenx SE
|
177,164 | $164,367,443 | |
| 7 | INSM |
INSMED Inc
|
826,431 | $88,114,072 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
381,366 | $71,422,223 |
All Filings in NAMS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,333,333 | 39,343 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $1,071,566 | 33,476 | Shares | Defined | 2026-05-08 | |
| 2025-12-31 | $1,436,560 | 40,951 | Shares | Defined | 2026-02-09 | |
| 2025-09-30 | $1,300,788 | 45,738 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $801,095 | 44,235 | Shares | Defined | 2025-08-12 | |
| 2025-03-31 | $678,149 | 33,129 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $589,712 | 22,946 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $262,877 | 15,836 | Shares | Defined | 2025-02-28 | |
| 2024-06-30 | $304,209 | 15,836 | Shares | Defined | 2025-05-29 | |
| No filing history on record for this holder in this stock. | ||||||